Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million , Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd

LAKE FOREST, Ill. , March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50%

  -- Reports Neurology Franchise Annual Net Sales of $108.1 Million , Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ®  Totaling $502.5 Million -- -- Repaid in Full Senior Secured Debt and Reduced Convertible Debt by $188.0 Million --

LAKE FOREST, Ill. , March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019 financial results on Monday, March 9, 2020 , after the close of markets.

LAKE FOREST, Ill. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated agreements (the “Purchase Agreements”) with a limited number of holders of Assertio’s currently

Also Announces its Senior Secured Debt Has Been Repaid in Full LAKE FOREST, Ill. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed definitive agreement (“Agreement”) with Collegium

Company Intends to Use Cash Proceeds to Retire its Outstanding Debt Company Intends to Use Improved Balance Sheet to Pursue Business Development, Strategic Partnerships and Investment Opportunities LAKE FOREST, Ill. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc.

LAKE FOREST, Ill. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed agreement (“Agreement”) with Alvogen , a global privately held pharmaceutical company, under which Alvogen will

LAKE FOREST, Ill. , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (NASDAQ: ASRT), today announced it has entered into an agreement with Alvogen , a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated

LAKE FOREST, Ill. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 31 st Annual Piper Jaffray Healthcare Conference in a session scheduled for 9:30 a.m.